The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review.

Wang, Xianhua; Hu, Shaobo; Su, Fei; Lin, Jie; Duan, Jianghui; Tan, Haidong; Tan, Huangying

Wang, Xianhua; Hu, Shaobo; Su, Fei; Lin, Jie; Duan, Jianghui; Tan, Haidong; Tan, Huangying.

Afiliación

Wang X; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Hu S; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.
Su F; Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Lin J; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.
Duan J; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.
Tan H; Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
Tan H; Department of Radiology, China-Japan Friendship Hospital, Beijing, China.

Ann Transl Med ; 10(22): 1254, 2022 Nov.

Article en En | MEDLINE | ID: mdl-36544653

Palabras clave

Surufatinib; adenocarcinoma; case report; extra-pulmonary neuroendocrine carcinoma (EP-NEC); large cell neuroendocrine carcinoma (LCNEC)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies Idioma: En Revista: Ann Transl Med Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google